This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ACX 31, ACX31
Accurexa is developing ACX-31, a program for the local delivery of a polymeric combination of temozolomide in combination with BCNU (carmustine), both chemotherapeutics, in the treatment of brain tumors. The therapeutic candidate will be delivered using Accurexa's BranchPoint delivery device.
Temodar (Temozolomide) is a nonclassic alkylating agent that is structurally and functionally similar to dacarbazine. Although the precise mechanism of cytotoxicity is unclear, Temodar methylates guanine residues in DNA and inhibits DNA, RNA, and protein synthesis.
Carmustine is a nitrosourea chemotherapeutic agent that alkylates DNA and RNA.
Additional information available to subscribers only: